Aadi Bioscience Inc. is a clinical-stage biopharmaceutical company. It focuses on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Aadi Bioscience Inc., formerly known as Aerpio Pharmaceuticals Inc., is based in LOS ANGELES.
| Revenue (Most Recent Fiscal Year) | $25.98M |
| Net Income (Most Recent Fiscal Year) | $-63.69M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.05 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.38 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 99.42% |
| Net Margin (Trailing 12 Months) | 99.42% |
| Return on Equity (Trailing 12 Months) | -56.73% |
| Return on Assets (Trailing 12 Months) | -48.68% |
| Current Ratio (Most Recent Fiscal Quarter) | 18.95 |
| Quick Ratio (Most Recent Fiscal Quarter) | 18.95 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.74 |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.71 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.36 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.26 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.16 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 47.11M |
| Free Float | 29.54M |
| Market Capitalization | $84.80M |
| Average Volume (Last 20 Days) | 0.14M |
| Beta (Past 60 Months) | 0.65 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 37.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 52.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |